美国上市生物科技公司CareDx(CDNA)今日盘前股价大跌8.94%,引发市场广泛关注。公司股价在过去一年里已经下跌近60%,让投资者对其前景越来越不看好。
分析人士指出,CareDx盘中大跌或与机构调低该股评级和目标价有关。其中,BTIG将CareDx的目标股价从40美元下调至35美元,反映出对公司业绩前景存疑虑。此外,加拿大皇家银行也将该股目标价从8美元大幅下调至5美元。
相关报道显示,CareDx去年第四季度营收同比增长11%,但略低于预期。公司产品线专注于移植后监测,但市场增长放缓。分析师们普遍认为,CareDx在未来几个季度需要推出新产品,以提振业务发展。不过该公司在研管线存在一些不确定性,增加了投资者的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.